93 related articles for article (PubMed ID: 3265236)
1. [Functional activity of the natural killers and macrophages in patients with breast tumors].
Andrianov IG; Voronov SM; Dobkin AN; Okulov VB; Orlov AB
Vopr Onkol; 1988; 34(12):1455-60. PubMed ID: 3265236
[TBL] [Abstract][Full Text] [Related]
2. [Immunomodulating activity of natural killers in patients with breast tumors using vasopressin and interleukin 2 in vitro].
Andrianov IG; Dobkin AN; Kiselev OI; Okulov VB; Semiglazov VF
Vopr Onkol; 1989; 35(10):1186-91. PubMed ID: 2596062
[TBL] [Abstract][Full Text] [Related]
3. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.
Konjević G; Spuzić I
Neoplasma; 1993; 40(2):81-5. PubMed ID: 8350959
[TBL] [Abstract][Full Text] [Related]
4. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells.
Konjević G; Spuzić I
J Clin Lab Immunol; 1992; 38(2):83-93. PubMed ID: 1343351
[TBL] [Abstract][Full Text] [Related]
6. [The effect of autoplasma of patients with breast cancer on the functional activity of natural killer cells and adhering mononuclear cells in peripheral blood in vitro].
Andrianov IG; Katashkova TN
Eksp Onkol; 1989; 11(5):64-6. PubMed ID: 2791959
[TBL] [Abstract][Full Text] [Related]
7. [NK (natural killer) and K (killer) cell activity in breast cancer. Relation of the stage of the disease to cytotoxic activity].
Garam T; Bakács T; Tótpál K; Svastits E; Ringwald G; Petrányi G
Orv Hetil; 1983 Jan; 124(1):15-8. PubMed ID: 6828317
[No Abstract] [Full Text] [Related]
8. Decreased response to interleukin-2 of cancer patients in terms of augmentation of natural killer cell activity.
Abe Y; Ajitsu S; Hamuro J; Ishikawa M; Sendo F
Jpn J Cancer Res; 1985 Oct; 76(10):1003-7. PubMed ID: 3935618
[TBL] [Abstract][Full Text] [Related]
9. Assessment of host immune response in breast cancer patients.
Akimoto M; Ishii H; Nakajima Y; Iwasaki H; Tan M; Abe R; Kasai M
Cancer Detect Prev; 1986; 9(3-4):311-7. PubMed ID: 3488806
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
11. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients.
Dewan MZ; Takada M; Terunuma H; Deng X; Ahmed S; Yamamoto N; Toi M
Biomed Pharmacother; 2009 Nov; 63(9):703-6. PubMed ID: 19269774
[TBL] [Abstract][Full Text] [Related]
12. Effect of human recombinant interleukin-2 on cytotoxic response of peripheral blood mononuclear cells in melanoma patients before surgery.
Jira M; Strejcek J; Chodounsky Z; Fuchsova M; Tomasova M; Faltyn J; Suchomelova M
Arch Geschwulstforsch; 1987; 57(5):379-84. PubMed ID: 3500690
[TBL] [Abstract][Full Text] [Related]
13. [Immunomodulatory effect of serum on NK cells in vitro in healthy individuals].
Konjević G; Spuzić I
Glas Srp Akad Nauka Med; 1994; (44):45-54. PubMed ID: 7590414
[TBL] [Abstract][Full Text] [Related]
14. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
15. [The response of peripheral blood lymphocytes from lung cancer patients to in-vitro treatment with recombinant interleukin-2].
Pogodina ON; Karaseva NA; Ivanov VA
Tsitologiia; 1997; 39(7):582-9. PubMed ID: 9490499
[TBL] [Abstract][Full Text] [Related]
16. [The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II].
Salozhin KV; Sura VV; Nasonov EL; Korneeva MN; Smirnova OI
Ter Arkh; 1989; 61(10):104-6. PubMed ID: 2609254
[TBL] [Abstract][Full Text] [Related]
17. Circulating killer cells in women undergoing needle-directed excisional breast biopsy.
Ohlsson-Wilhelm BM; Wang G
Eur J Histochem; 1994; 38 Suppl 1():77-82. PubMed ID: 8547715
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production.
Kubo M; Morisaki T; Matsumoto K; Tasaki A; Yamanaka N; Nakashima H; Kuroki H; Nakamura K; Nakamura M; Katano M
Cancer Immunol Immunother; 2005 May; 54(5):468-76. PubMed ID: 15592829
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients.
Wong PY; Staren ED; Tereshkova N; Braun DP
J Surg Res; 1998 Apr; 76(1):95-103. PubMed ID: 9695747
[TBL] [Abstract][Full Text] [Related]
20. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages.
Li H; Cao MY; Lee Y; Lee V; Feng N; Benatar T; Jin H; Wang M; Der S; Wright JA; Young AH
Cancer Immunol Immunother; 2005 Nov; 54(11):1115-26. PubMed ID: 15891881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
